<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928289</url>
  </required_header>
  <id_info>
    <org_study_id>SIGHTVISCO-001</org_study_id>
    <nct_id>NCT02928289</nct_id>
  </id_info>
  <brief_title>Randomized Study of the Safety and Effectiveness of the Sight Sciences VISCO™360 Viscosurgical System Versus SLT in Primary Open Angle Glaucoma (VISCO360 Study)</brief_title>
  <official_title>Multi-Center, Prospective, Randomized, Controlled Clinical Evaluation of the Safety and Effectiveness of the Sight Sciences VISCO™360 Viscosurgical System in Canaloplasty Versus Selective Laser Trabeculoplasty in the Reduction of IOP in Primary Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sight Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sight Sciences, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of the Sight Sciences&#xD;
      VISCO™360 Viscosurgical System in reducing intraocular pressure (IOP) in adult, pseudophakic&#xD;
      subjects with open-angle glaucoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor enrollment&#xD;
  </why_stopped>
  <start_date type="Actual">January 23, 2017</start_date>
  <completion_date type="Actual">January 17, 2019</completion_date>
  <primary_completion_date type="Actual">January 17, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in diurnal IOP (Measured in mm Hg)</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement is performed at 12 months following wash-out of glaucoma medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving a ≥ 20% reduction in mean diurnal IOP</measure>
    <time_frame>12 months</time_frame>
    <description>Measurement is performed at 12 months following wash-out of glaucoma medication</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Open-Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>VISCO360 ab interno canaloplasty surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to this arm will undergo a surgical procedure in which the VISCO360 Viscosurgical System will be used to microcatheterize and viscodilate Schlemm's canal (i.e., canaloplasty).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selective Laser Trabeculoplasty (SLT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to this arm will undergo the SLT procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VISCO360 ab interno canaloplasty surgery</intervention_name>
    <description>360 degrees of viscodilation of Schlemm's canal</description>
    <arm_group_label>VISCO360 ab interno canaloplasty surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Selective Laser Trabeculoplasty (SLT)</intervention_name>
    <description>360 degrees of selective laser trabeculoplasty</description>
    <arm_group_label>Selective Laser Trabeculoplasty (SLT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with primary open-angle glaucoma (POAG) in the study eye.&#xD;
&#xD;
          -  Pseudophakic with Posterior Chamber IOL (PCIOL)&#xD;
&#xD;
          -  Able and willing to attend follow up visits for two years post-operative&#xD;
&#xD;
          -  Able and willing to sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Phakia or aphakia&#xD;
&#xD;
          -  Previous glaucoma procedure with or without an implantable glaucoma device (including&#xD;
             incisional surgery, ALT, iridectomy/iridotomy, etc.) [Subjects with one prior SLT&#xD;
             application (&gt;3 months prior to screening) or prior ECP (performed &gt; 12 months prior&#xD;
             to screening) can be enrolled].&#xD;
&#xD;
          -  Use of more than 3 ocular hypotensive medications (combination medications count as 2&#xD;
             medications)&#xD;
&#xD;
          -  Diagnosis of acute angle closure, traumatic, congenital, malignant, uveitic,&#xD;
             pseudoexfoliative, pigmentary or neovascular glaucoma&#xD;
&#xD;
          -  Abnormal angle anatomy as determined by gonioscopy (e.g. peripheral anterior&#xD;
             synechiae, rubeosis or other angle abnormalities)&#xD;
&#xD;
          -  Participation in any clinical trial ≤ 30 days prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vold Vision</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Vision Medical Group</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dean McGee Eye Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wills Eye Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Paso Eye Surgeons</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Associates</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 6, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2016</study_first_posted>
  <last_update_submitted>February 26, 2019</last_update_submitted>
  <last_update_submitted_qc>February 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

